Colgate-Palmolive Work in process increased by 8.7% to $50.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.7%, from $53.00M to $50.00M. Over 5 years (FY 2020 to FY 2025), Work in process shows relatively stable performance with a 0.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.00M | $44.00M | $39.00M | $50.00M | $53.00M | $51.00M | $48.00M | $55.00M | $47.00M | $52.00M | $46.00M | $43.00M | $43.00M | $49.00M | $46.00M | $53.00M | $53.00M | $53.00M | $46.00M | $50.00M |
| QoQ Change | — | -8.3% | -11.4% | +28.2% | +6.0% | -3.8% | -5.9% | +14.6% | -14.5% | +10.6% | -11.5% | -6.5% | +0.0% | +14.0% | -6.1% | +15.2% | +0.0% | +0.0% | -13.2% | +8.7% |
| YoY Change | — | — | — | — | +10.4% | +15.9% | +23.1% | +10.0% | -11.3% | +2.0% | -4.2% | -21.8% | -8.5% | -5.8% | +0.0% | +23.3% | +23.3% | +8.2% | +0.0% | -5.7% |
| % of Inventories | 51.6% | 51.2% | 39.0% | 39.4% | 48.2% | 50.5% | 32.4% | 41.0% | 38.8% | 50.5% | 35.7% | 29.9% | 32.6% | 41.9% | 38.0% | 41.4% | 46.5% | 54.1% | 36.8% | 48.5% |
| Share Change | — | -0.5pp | -12.2pp | +0.4pp | +8.8pp | +2.3pp | -18.1pp | +8.6pp | -2.2pp | +11.6pp | -14.8pp | -5.8pp | +2.7pp | +9.3pp | -3.9pp | +3.4pp | +5.1pp | +7.6pp | -17.3pp | +11.7pp |